Drugs / TARP peptide
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00972309 | May 2009 → Feb 2015 | prostate cancer | National Cancer Institute (NCI) | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TARP peptide | “Will receive an admixture of the wildtype and epitope enhanced TARP peptides emulsified with Montanide ISA 51 VG and granulocyte-macrophage colony-stimulating factor (GM-CSF)....” NCT00972309 ↗ |
| Modality | Vaccine | “The TARP prostate cancer vaccine is made from pieces of the TARP protein called peptides” NCT00972309 ↗ |
| Route | Subcutaneous | “TARP peptide will be administered subcutaneously” NCT00972309 ↗ |